CN100358512C - 包含腺苷受体激动剂或拮抗剂的药物组合物 - Google Patents

包含腺苷受体激动剂或拮抗剂的药物组合物 Download PDF

Info

Publication number
CN100358512C
CN100358512C CNB008148007A CN00814800A CN100358512C CN 100358512 C CN100358512 C CN 100358512C CN B008148007 A CNB008148007 A CN B008148007A CN 00814800 A CN00814800 A CN 00814800A CN 100358512 C CN100358512 C CN 100358512C
Authority
CN
China
Prior art keywords
adenosine
active ingredient
pharmaceutical composition
drug
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB008148007A
Other languages
English (en)
Chinese (zh)
Other versions
CN1391468A (zh
Inventor
P·菲施曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Can Fite Biopharma Ltd
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL13186499A external-priority patent/IL131864A0/xx
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Publication of CN1391468A publication Critical patent/CN1391468A/zh
Application granted granted Critical
Publication of CN100358512C publication Critical patent/CN100358512C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB008148007A 1999-09-10 2000-09-08 包含腺苷受体激动剂或拮抗剂的药物组合物 Expired - Lifetime CN100358512C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IL131864 1999-09-10
IL13186499A IL131864A0 (en) 1999-09-10 1999-09-10 Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
IL13368099A IL133680A0 (en) 1999-09-10 1999-12-23 Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
IL133680 1999-12-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2007101850427A Division CN101164548A (zh) 1999-09-10 2000-09-08 包含腺苷受体激动剂或拮抗剂的药物组合物

Publications (2)

Publication Number Publication Date
CN1391468A CN1391468A (zh) 2003-01-15
CN100358512C true CN100358512C (zh) 2008-01-02

Family

ID=26323880

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008148007A Expired - Lifetime CN100358512C (zh) 1999-09-10 2000-09-08 包含腺苷受体激动剂或拮抗剂的药物组合物

Country Status (19)

Country Link
US (2) US7064112B1 (https=)
EP (1) EP1261322B1 (https=)
JP (2) JP4980530B2 (https=)
KR (2) KR100584797B1 (https=)
CN (1) CN100358512C (https=)
AU (1) AU782826B2 (https=)
BR (1) BR0013905A (https=)
CA (1) CA2384111C (https=)
DE (1) DE60037277T2 (https=)
DK (1) DK1261322T3 (https=)
ES (1) ES2296637T3 (https=)
HK (1) HK1052653B (https=)
HU (1) HU226913B1 (https=)
IL (1) IL133680A0 (https=)
MX (1) MXPA02002546A (https=)
PL (1) PL199852B1 (https=)
PT (1) PT1261322E (https=)
RU (1) RU2239455C2 (https=)
WO (1) WO2001019360A2 (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL121272A (en) * 1997-07-10 2000-06-01 Can Fite Technologies Ltd Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia
AU8181701A (en) 2000-06-21 2002-01-02 Hoffmann La Roche Benzothiazole derivatives
JP4012070B2 (ja) * 2001-01-16 2007-11-21 カン−フィテ・バイオファーマ・リミテッド ウイルスの複製を阻害するためのアデノシンａ３受容体アゴニストの使用
US20020115635A1 (en) * 2001-02-21 2002-08-22 Pnina Fishman Modulation of GSK-3beta activity and its different uses
US20040204481A1 (en) * 2001-04-12 2004-10-14 Pnina Fishman Activation of natural killer cells by adenosine A3 receptor agonists
US7049303B2 (en) 2001-11-07 2006-05-23 Medical Research Council Inhibition of viruses
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
EP1554583B1 (en) * 2002-10-22 2007-08-22 Can-Fite Biopharma Ltd. The use of the a3 adenosine receptor as a marker for a disease state
US7087761B2 (en) 2003-01-07 2006-08-08 Hoffmann-La Roche Inc. Cyclization process for substituted benzothiazole derivatives
CN1956983B (zh) 2004-05-24 2010-05-26 弗·哈夫曼-拉罗切有限公司 4-羟基-4-甲基-哌啶-1-甲酸(4-甲氧基-7-吗啉-4-基-苯并噻唑-2-基)-酰胺
CN103087133B (zh) 2004-05-26 2016-09-14 伊诺泰克制药公司 嘌呤衍生物作为腺苷a1受体激动剂及其用法
US7825102B2 (en) 2004-07-28 2010-11-02 Can-Fite Biopharma Ltd. Treatment of dry eye conditions
CN101437526A (zh) 2004-09-20 2009-05-20 伊诺泰克制药公司 嘌呤衍生物及其用法
EP1799221A1 (en) * 2004-10-15 2007-06-27 Cv Therapeutics, Inc. Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists
JP4633123B2 (ja) 2004-11-05 2011-02-16 エフ．ホフマン−ラ ロシュ アーゲー イソニコチン酸誘導体の製造方法
JP2008519029A (ja) * 2004-11-08 2008-06-05 キャン−ファイト・バイオファーマ・リミテッド 加速骨吸収の治療的処置
WO2007040565A2 (en) * 2004-11-22 2007-04-12 King Pharmaceuticals Research & Development, Inc. Enhancing treatment of cancer and hif-1 mediated disoders with adenosine a3 receptor antagonists
DE602006012815D1 (de) 2005-03-23 2010-04-22 Hoffmann La Roche Acetylenylpyrazolopyrimidinderivate als mglur2-antagonsten
AU2006298829B2 (en) 2005-09-27 2011-03-03 F. Hoffmann-La Roche Ag Oxadiazolyl pyrazolo-pyrimidines as mGluR2 antagonists
EA015683B1 (ru) 2005-11-30 2011-10-31 Инотек Фармасьютикалз Корпорейшн Производные пурина и способы их применения
BRPI0621052A2 (pt) * 2006-01-27 2012-07-17 Can Fite Biopharma Ltd uso de um agonista de receptor de adenosina a3 (a3ar)
WO2008023362A2 (en) * 2006-08-21 2008-02-28 Can-Fite Biopharma Ltd. Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
MX2009003750A (es) * 2006-10-06 2009-06-18 Univ Pennsylvania Suministro eficiente de antagonistas del receptor de adenosina a3 de especies cruzadas, para reducir la presion intraocular.
GB0625100D0 (en) * 2006-12-15 2007-01-24 Univ Murcia Epigallocatechin-3-gallate compositions for cancer therapy and chemoprotection
US20090088403A1 (en) * 2007-05-07 2009-04-02 Randy Blakely A3 adenosine receptors as targets for the modulation of central serotonergic signaling
CA2694983A1 (en) * 2007-07-17 2009-01-22 Combinatorx, Incorporated Treatments of b-cell proliferative disorders
US20090047243A1 (en) * 2007-07-17 2009-02-19 Richard Rickles Combinations for the treatment of b-cell proliferative disorders
WO2009151569A2 (en) * 2008-06-09 2009-12-17 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
WO2010027935A1 (en) * 2008-09-08 2010-03-11 Merck Sharp & Dohme Corp. Ahcy hydrolase inhibitors for treatment of hyper homocysteinemia
JP5849044B2 (ja) 2009-05-17 2016-01-27 キャン−ファイト バイオファーマ リミテッド 眼圧低下のためのａ３アデノシン受容体作動薬
WO2011010306A1 (en) 2009-07-21 2011-01-27 Ramot At Tel-Aviv University Ltd. A3 adenosine receptor ligands for modulation of pigmentation
WO2011074903A2 (ko) * 2009-12-17 2011-06-23 이화여자대학교 산학협력단 Ａ3 아데노신 수용체 효능제를 포함하는 약제학적 조성물
LT2523669T (lt) 2010-01-11 2017-04-25 Inotek Pharmaceuticals Corporation Akispūdžio mažinimo būdas, derinys ir rinkinys
MX2012010006A (es) 2010-03-03 2013-01-17 Us Gov Health & Human Serv Agonistas de a3ar para el tratamiento de uveitis.
PH12012501906A1 (en) 2010-03-26 2013-01-14 Inotek Pharmaceuticals Corp Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof
WO2011123518A1 (en) 2010-03-31 2011-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
UA117095C2 (uk) 2011-12-22 2018-06-25 Аліос Біофарма, Інк. Нуклеозидна сполука або її фармацевтично прийнятна сіль
CN104159589A (zh) * 2012-01-23 2014-11-19 坎-菲特生物药物有限公司 肝脏状况的治疗
PT2807178T (pt) 2012-01-26 2017-08-08 Inotek Pharmaceuticals Corp Polimorfos anidros de nitrato de (2r,3s,4r,5r)-5-(6-(ciclopentilamino)-9h-purin-9-il)-3,4-dihidroxitetrahidrofuran-2-il)}metilo e seus processos de preparação
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US8822460B2 (en) 2012-04-06 2014-09-02 Janssen Pharmaceutica Nv Fused cyclopentyl antagonists of CCR2
AU2013290418B2 (en) 2012-07-19 2017-08-03 Chaozhong Cai Octahydro-cyclopentapyrrolyl antagonists of CCR2
JP6140825B2 (ja) 2012-08-09 2017-05-31 キャン−ファイト バイオファーマ リミテッドＣａｎ−Ｆｉｔｅ ＢｉｏＰｈａｒｍａ Ｌｔｄ． 性機能不全の治療に使用するためのａ３アデノシン受容体リガンド
NZ630759A (en) 2013-03-15 2017-07-28 Inotek Pharmaceuticals Corp Ophthalmic formulations comprising an a1 agonist
IL242723B (en) 2015-11-23 2019-12-31 Can Fite Biopharma Ltd A3 adenosine receptor ligand for the treatment of ectopic fat accumulation
KR102445887B1 (ko) 2016-04-21 2022-09-21 아스트로사이트 파마슈티컬스, 인코포레이티드 신경계 및 심혈관계 병태 치료를 위한 화합물 및 방법
IL254535A0 (en) * 2017-09-17 2017-11-30 Can Fite Biopharma Ltd Adenosine a3 receptor ligand for use in the management of cytokine release syndrome
IL276358B2 (en) 2018-02-09 2024-11-01 Astrocyte Pharmaceuticals Inc Compounds and methods for treating addiction and related disorders
EA202190576A1 (ru) 2018-09-26 2021-09-03 Астросайт Фармасьютикалс, Инк. Полиморфные соединения и их применение
IL264112A (en) 2019-01-06 2020-07-30 Fishman Pnina An a3 adenosine receptor ligand for use for reducing level of adipocytes
IT202300014340A1 (it) 2023-07-10 2025-01-10 Consiglio Nazionale Ricerche Trattamento di malattie associate alla disfunzione del gene ocrl.

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021195A1 (en) * 1993-03-15 1994-09-29 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
WO1995002604A1 (en) * 1993-07-13 1995-01-26 The United States Of America, Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists
GB2289218A (en) * 1994-05-06 1995-11-15 Merck & Co Inc Inhibition of TNFalpha production with agonists of the A2b subtype of the adenosine receptor
US5688774A (en) * 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
WO1998050047A1 (en) * 1997-05-09 1998-11-12 Trustees Of The University Of Pennsylvania Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
WO1999002143A2 (en) * 1997-07-10 1999-01-21 Can-Fite Technologies Ltd. Medicament comprising adenosine
WO1999006053A1 (en) * 1997-07-29 1999-02-11 Medco Research, Inc. N6-substituted-adenosine-5'-uronamides as adenosine receptor modulators
WO1999020284A1 (en) * 1997-10-23 1999-04-29 Trustees Of The University Of Pennsylvania Methods for reducing ischemic injury of the heart via the sequential administration of monophosphoryl lipid a and adenosine receptor agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2071770C1 (ru) 1994-12-14 1997-01-20 Владислав Алексеевич Шматко Способ лечения рака шейки матки и яичников
RU2071771C1 (ru) 1995-01-11 1997-01-20 Владислав Алексеевич Шматко Способ лечения рака молочной железы
US6048865A (en) * 1997-07-29 2000-04-11 Medco Research, Inc. N6 -substituted-adenosine-5'-uronamides as adenosine receptor modulator
EP1011608A4 (en) 1998-06-08 2002-05-15 Epigenesis Pharmaceuticals Inc COMPOSITION AND METHOD FOR THE PREVENTION AND TREATMENT OF HEART AND NEUTRAL FAILURE OR DAMAGE RELATED TO ISCHEMIA, ENDOTOXIN RELEASE, ARDS OR CALLED BY THE ADDITION OF SPECIFIC MEDICINES
US6448253B1 (en) 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
IL127947A0 (en) * 1999-01-07 1999-11-30 Can Fite Technologies Ltd Pharmaceutical use of adenosine agonists
CA2361614C (en) 1999-02-01 2008-08-26 University Of Virginia Patent Foundation Compositions for treating inflammatory response
IL131096A (en) 1999-07-26 2004-09-27 Can Fite Technologies Ltd Method for preparing a composition derived from muscle tissue

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021195A1 (en) * 1993-03-15 1994-09-29 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
WO1995002604A1 (en) * 1993-07-13 1995-01-26 The United States Of America, Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists
US5688774A (en) * 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
GB2289218A (en) * 1994-05-06 1995-11-15 Merck & Co Inc Inhibition of TNFalpha production with agonists of the A2b subtype of the adenosine receptor
WO1998050047A1 (en) * 1997-05-09 1998-11-12 Trustees Of The University Of Pennsylvania Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
WO1999002143A2 (en) * 1997-07-10 1999-01-21 Can-Fite Technologies Ltd. Medicament comprising adenosine
WO1999006053A1 (en) * 1997-07-29 1999-02-11 Medco Research, Inc. N6-substituted-adenosine-5'-uronamides as adenosine receptor modulators
WO1999020284A1 (en) * 1997-10-23 1999-04-29 Trustees Of The University Of Pennsylvania Methods for reducing ischemic injury of the heart via the sequential administration of monophosphoryl lipid a and adenosine receptor agents

Also Published As

Publication number Publication date
US7064112B1 (en) 2006-06-20
ES2296637T3 (es) 2008-05-01
HU226913B1 (en) 2010-03-01
IL133680A0 (en) 2001-04-30
JP2003514771A (ja) 2003-04-22
BR0013905A (pt) 2003-07-15
HK1052653B (zh) 2008-08-01
JP2007204496A (ja) 2007-08-16
PL199852B1 (pl) 2008-11-28
PL356469A1 (en) 2004-06-28
AU782826B2 (en) 2005-09-01
CN1391468A (zh) 2003-01-15
KR100584797B1 (ko) 2006-06-02
RU2002109228A (ru) 2004-01-10
CA2384111C (en) 2008-05-27
DE60037277T2 (de) 2008-10-09
PT1261322E (pt) 2008-01-09
HUP0203870A3 (en) 2005-07-28
JP4980530B2 (ja) 2012-07-18
MXPA02002546A (es) 2003-07-21
HK1052653A1 (zh) 2003-09-26
CA2384111A1 (en) 2001-03-22
EP1261322A2 (en) 2002-12-04
WO2001019360A3 (en) 2002-09-19
KR20020038749A (ko) 2002-05-23
AU6863400A (en) 2001-04-17
DE60037277D1 (de) 2008-01-10
RU2239455C2 (ru) 2004-11-10
DK1261322T3 (da) 2008-04-07
KR20060036490A (ko) 2006-04-28
WO2001019360A2 (en) 2001-03-22
KR100674529B1 (ko) 2007-01-30
HUP0203870A2 (hu) 2003-03-28
US20060084626A1 (en) 2006-04-20
EP1261322B1 (en) 2007-11-28

Similar Documents

Publication Publication Date Title
CN100358512C (zh) 包含腺苷受体激动剂或拮抗剂的药物组合物
US6579857B1 (en) Combination cancer therapy comprising adenosine and deaminase enzyme inhibitors
Bar-Yehuda et al. Resistance of muscle to tumor metastases: a role for a3 adenosine receptor agonists
PT1385498E (pt) Ácidos gordos como factores de sobrevivência e activação de neutrófilos
US6664242B2 (en) Composition and method comprising CPT-11 and a pyrimidine derivative for the treatment of cancer
CN112165945A (zh) 治疗淋巴样恶性疾病之方法
EP4424316A1 (en) Antitumor pharmaceutical composition comprising azvudine and chemotherapeutic agent
EP1156828B1 (en) Combination therapy for lymphoproliferative diseases
US6790839B2 (en) Pharmaceutical administration of adenosine agonists
HK1118707A (en) Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
US20040248915A1 (en) Method for administration of troxacitabine
CN112533605A (zh) 用于治疗癌症的组合疗法
JP2025525510A (ja) Ｂｃｌ－２阻害剤を含む癌併用療法
US20020037871A1 (en) Pharmaceutical use of adenosine agonists
CN113727719A (zh) 血癌的新型治疗方法及新型治疗剂
HK40061085A (en) Novel therapeutic method and novel therapeutic agent for hematological cancer
HK40040825A (zh) 用於治疗癌症的组合疗法
CN101164548A (zh) 包含腺苷受体激动剂或拮抗剂的药物组合物
ZA200206864B (en) A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1052653

Country of ref document: HK

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20080102